ID24942A - Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4 - Google Patents

Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4

Info

Publication number
ID24942A
ID24942A IDW20000820A ID20000820A ID24942A ID 24942 A ID24942 A ID 24942A ID W20000820 A IDW20000820 A ID W20000820A ID 20000820 A ID20000820 A ID 20000820A ID 24942 A ID24942 A ID 24942A
Authority
ID
Indonesia
Prior art keywords
bioisosters
catecol
indazole
replacement
compounds based
Prior art date
Application number
IDW20000820A
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID24942A publication Critical patent/ID24942A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW20000820A 1997-11-04 1998-10-09 Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4 ID24942A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6416097P 1997-11-04 1997-11-04

Publications (1)

Publication Number Publication Date
ID24942A true ID24942A (id) 2000-08-31

Family

ID=22053970

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000820A ID24942A (id) 1997-11-04 1998-10-09 Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4

Country Status (34)

Country Link
US (2) US6716978B2 (id)
EP (1) EP1040100A1 (id)
JP (1) JP2001521925A (id)
KR (1) KR20010031783A (id)
CN (1) CN1281441A (id)
AP (1) AP1122A (id)
AR (1) AR016413A1 (id)
AU (1) AU754184B2 (id)
BG (1) BG104391A (id)
BR (1) BR9813938A (id)
CA (1) CA2309175A1 (id)
CZ (1) CZ20001623A3 (id)
DZ (1) DZ2639A1 (id)
EA (1) EA200000385A1 (id)
HN (1) HN1998000172A (id)
HR (1) HRP20000262A2 (id)
HU (1) HUP0100330A3 (id)
ID (1) ID24942A (id)
IL (1) IL135714A0 (id)
IS (1) IS5452A (id)
MA (1) MA26562A1 (id)
NO (1) NO20002127L (id)
NZ (1) NZ503995A (id)
OA (1) OA11353A (id)
PA (1) PA8462601A1 (id)
PE (1) PE131099A1 (id)
PL (1) PL340799A1 (id)
SK (1) SK6262000A3 (id)
TN (1) TNSN98199A1 (id)
TR (1) TR200001256T2 (id)
UY (1) UY25232A1 (id)
WO (1) WO1999023076A1 (id)
YU (1) YU25400A (id)
ZA (1) ZA9810042B (id)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754734B2 (en) * 1997-11-04 2002-11-21 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
MXPA02010222A (es) 2000-04-18 2003-05-23 Agouron Pharma Pirazoles para inhibir proteina cinasa.
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
ES2427930T3 (es) * 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
JP2006508996A (ja) * 2002-11-27 2006-03-16 アルタナ　ファルマ　アクチエンゲゼルシャフト 悪液質の治療における使用のための、ｐｄｅ４及びｐｄｅ３／４インヒビター
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2005089457A (ja) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
RS53543B1 (en) * 2004-03-03 2015-02-27 Takeda Gmbh NEW HYDROXY-6-HETEROARYLPHENANTRIDINES AND THEIR USE AS PDE4 INHIBITORS
US7432266B2 (en) * 2004-10-15 2008-10-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US7645752B2 (en) 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
JP5131990B2 (ja) 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害剤およびその使用方法
AU2008224541B2 (en) 2007-03-14 2013-08-22 Sun Pharmaceutical Industries Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
US8877816B2 (en) * 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
JP5216912B2 (ja) 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
JP5507567B2 (ja) 2008-09-26 2014-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのアザインダゾール化合物
CA2778060A1 (en) 2009-10-21 2011-04-28 Boehringer Ingelheim International Gmbh Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
WO2011056440A1 (en) 2009-10-27 2011-05-12 Boehringer Ingelheim International Gmbh Heterocyclic compounds as ccr1 receptor antagonists
EP2509952A1 (en) * 2009-12-08 2012-10-17 Boehringer Ingelheim International GmbH Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
WO2011076878A1 (en) * 2009-12-23 2011-06-30 Palau Pharma, S.A. Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
EP2563787B1 (en) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazole amide compounds as ccr1 receptor antagonists
CN102958927A (zh) 2010-05-12 2013-03-06 Abbvie公司 激酶的吲唑抑制剂
JP5684406B2 (ja) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのピラゾロピペリジン化合物
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
SI3169666T1 (en) 2014-07-15 2018-08-31 Gruenenthal Gmbh SUBSTITUTED DERIVATIVES AZASPIRO (4.5) DECAN
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11457370B2 (en) 2020-12-11 2022-09-27 Hewlett Packard Enterprise Development Lp System and method for seamless live upgrade of access points using neighbor data
IL304014A (en) 2020-12-30 2023-08-01 Tyra Biosciences Inc Indazole compounds as kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2064304A1 (de) * 1970-12-29 1972-07-20 Agfa-Gevaert Ag, 5090 Leverkusen Lichtempfindliches farbfotografisches Material
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
IL127036A (en) * 1996-06-25 2001-06-14 Pfizer History of Inverted Indazol and Phdephodesterase (PDE) IV and TNF-Containing Pharmaceuticals Containing Them
EP0816357B1 (en) * 1996-06-27 2002-01-09 Pfizer Inc. Substituted indazole derivatives
EA002113B1 (ru) * 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
ES2172882T3 (es) * 1997-05-08 2002-10-01 Pfizer Prod Inc Procedimientos y productos intermedios para la preparacion de derivados indazol sustituidos.
AU754734B2 (en) * 1997-11-04 2002-11-21 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds

Also Published As

Publication number Publication date
JP2001521925A (ja) 2001-11-13
NZ503995A (en) 2003-02-28
TR200001256T2 (tr) 2000-11-21
ZA9810042B (en) 2000-05-03
NO20002127L (no) 2000-07-03
DZ2639A1 (fr) 2003-03-08
MA26562A1 (fr) 2004-12-20
PL340799A1 (en) 2001-02-26
AU9277798A (en) 1999-05-24
NO20002127D0 (no) 2000-04-26
AR016413A1 (es) 2001-07-04
HN1998000172A (es) 1999-01-08
US6716978B2 (en) 2004-04-06
PE131099A1 (es) 1999-12-17
OA11353A (en) 2003-12-19
UY25232A1 (es) 2000-12-29
KR20010031783A (ko) 2001-04-16
AU754184B2 (en) 2002-11-07
EP1040100A1 (en) 2000-10-04
US20030158189A1 (en) 2003-08-21
AP1122A (en) 2002-11-29
BG104391A (en) 2000-12-29
IS5452A (is) 2000-04-14
SK6262000A3 (en) 2002-03-05
YU25400A (sh) 2003-07-07
WO1999023076A1 (en) 1999-05-14
HUP0100330A2 (hu) 2002-02-28
CZ20001623A3 (cs) 2001-08-15
TNSN98199A1 (fr) 2005-03-15
US20020058687A1 (en) 2002-05-16
CN1281441A (zh) 2001-01-24
EA200000385A1 (ru) 2000-10-30
AP9801376A0 (en) 1998-12-31
PA8462601A1 (es) 2000-05-24
HUP0100330A3 (en) 2002-03-28
HRP20000262A2 (en) 2000-10-31
IL135714A0 (en) 2001-05-20
CA2309175A1 (en) 1999-05-14
BR9813938A (pt) 2000-09-26

Similar Documents

Publication Publication Date Title
ID24942A (id) Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4
ID23921A (id) Penggantian indazola bioisostere katekol pada senyawa-senyawa aktif untuk terapi
NO971537L (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser
NO20014858L (no) Anvendelse av CYP2D6 inhibitorer i kombinasjonsterapi
DK0934301T3 (da) Aminothiophencarboxylsyreamider og anvendelse deraf som phosphodiesteraseinhibitorer
DK1268481T3 (da) Inaseinkibitorer som terapeutiske midler
HK1046277B (zh) 具有組蛋白脫乙酰酶抑制劑活性的苯甲酰胺製劑
AU2001240542A1 (en) Heterocyclic compounds and their use as parp inhibitors
HUP0203289A3 (en) Benzamides and related inhibitors of factor xa
DE69718480D1 (de) Heterocyclische metalloprotease inhibitoren
DE50310980D1 (de) VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE
IL145907A0 (en) Use of glucosylceramide synthesis inhibitors in therapy
IS5302A (is) Nýjar amidínóafleiður og notkun þeirra sem þrombínhemla
HK1043981A1 (zh) 取代的4-聯芳基丁酸和5-聯芳基戊酸衍生物作為治療呼吸疾病的基質金屬蛋白酶抑制劑的用途
EE03745B1 (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
ID20794A (id) Penggunaan inhibitor penukar natrium-hidrogen untuk pembuatan sediaan farmasi untuk pengobatan gangguan yang disebabkan oleh protozoa
GB9502858D0 (en) Novel use of matrix metalloproteinase inhibitors
ATE228122T1 (de) Umgekehrt hydroxamat inhibitoren von matrix metalloproteinasen
WO1998047494A3 (en) Novel use of matrix metalloproteinase inhibitors
DE60012208D1 (de) Type 1 inhibitorkristalle als inhibitoren des natrium-protonen austauschs
GB9927780D0 (en) The therapeutic use of matrix metalloproteinase inhibitors
GB9627016D0 (en) Novel use of matrix metalloproteinase inhibitors
GB9828845D0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases